Shield TherapeuticsSTU:1JS -2.16% Market Cap is €76.92 Mil as of Jun. 25, 2026. The stock has 5 warning signs investors should review. Among 1,023 Drug Manufacturers companies, Shield Therapeutics ranks worse than 62.07% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Shield Therapeutics's share price for the quarter that ended in Dec. 2025 was €0.11. Shield Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 1,067.84 Mil. Therefore, Shield Therapeutics's market cap for the quarter that ended in Dec. 2025 was €117.46 Mil.
Shield Therapeutics's quarterly market cap
increased
from Dec. 2024 (€26.04 Mil) to Jun. 2025 (€28.13 Mil) and
increased
from Jun. 2025 (€28.13 Mil) to Dec. 2025 (€117.46 Mil).
Shield Therapeutics's annual market cap
declined
from Dec. 2023 (€60.22 Mil) to Dec. 2024 (€26.04 Mil) but then
increased
from Dec. 2024 (€26.04 Mil) to Dec. 2025 (€117.46 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Shield Therapeutics's Enterprise Value for Today is €93.19 Mil.
Shield Therapeutics (STU:1JS) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Shield Therapeutics Market Cap Related Terms
Shield Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Shield Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shield Therapeutics Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Shield Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Shield Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shield Therapeutics (STU:1JS) has a Market Cap of €76.92 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Shield Therapeutics and its competitors. According to the industry distribution chart, Shield Therapeutics ranks #635 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 62.1%.
Is Shield Therapeutics' Market Cap too high?
Shield Therapeutics' current Market Cap is €76.92 Mil. Based on the distribution chart, Shield Therapeutics ranks #635 out of 1023 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does Shield Therapeutics' Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shield Therapeutics ranks #635 out of 1023 companies for Market Cap. This places Shield Therapeutics in the lower half of its industry. The industry median Market Cap is 206.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 206.50, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Shield Therapeutics and its competitors. For the Drug Manufacturers industry, the median Market Cap is 206.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shield Therapeutics's current Market Cap is €76.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shield Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Shield Therapeutics (STU:1JS) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.09, compared to a current price of €0.07 — trading 24.4% below its estimated fair value. The current Market Cap is €76.92 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Shield Therapeutics (STU:1JS), the current Market Cap is €76.92 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1JS has been successfully added to your 